ICON’s method development teams have extensive experience developing and validating robust bioanalytical methods in blood, urine and tissue specimens to support pre-clinical and Phase I through Phase IV clinical trials with an average method development/validation time of 12 days.

Through our dedicated and highly experienced Quality Assurance groups, we deliver QA approved data to our sponsors within 5 days of study completion or on a run-by-run basis if desired. All reports are produced to appropriate regulatory standards, either in the client’s own format or in the default ICON standard, and final QA reviewed study reports are available to sponsors within 12 days from study completion.